Exploring gene therapy
Gene therapy is a method to treat diseases that are caused by defective, damaged or missing genes. Gene therapy contains genetic material that repairs or replaces the defective, damaged or missing genes.
Gene therapies are one time, very high cost treatments. For example, Zolgensma is approved for a very rare disease and is available at a cost of $2.5 million per treatment. We are exploring our approach to covering these treatments while ensuring plan sustainability.
Expanding the Reference Drug Program (RDP)
The RDP balances drug plan costs with maintaining therapeutic choices for plan members. It aims to maintain access, and provide support and guidance on treatments.
We’ll continue to enhance our RDP offering by adding more drugs to this program. This will provide plan sponsors additional value, as part of our overall drug cost-saving strategy.
Continuing pharmaceutical negotiations
We’ll continue to negotiate agreements with drug manufacturers. This allows us to give increased value and access to specialty drugs for plan members through reduced costs.
These agreements help us give plan members more access to specialty drugs, while managing the costs for plan sponsors.